The Simple Truth
Why this exists and what it’s supposed to do.
Semaglutide exists because the natural hormone it copies survives about two minutes.
After you eat, your gut releases GLP-1, which tells your brain you are full and your pancreas to handle the glucose. An enzyme destroys it almost immediately.
What it is supposed to do: make you much less hungry, for a week per injection — which is why it is used for weight loss and type 2 diabetes. It also has proven cardiovascular benefit.
This is among the best-evidenced compounds on the site: large randomised trials and approved products. The drug is not a new idea, it is an existing hormone made to last.
A molecule is not the same as every product bearing its name
Semaglutide is a glucagon-like peptide-1 receptor agonist. Its evidence spans different prescription formulations and clinical questions. The fact that products share an active ingredient does not make every route, formulation or indication interchangeable. An injectable obesity trial cannot, by itself, validate an oral preparation or a seller's reconstituted research vial.
Regulatory claims should name a product and indication rather than treating approval as a property of a generic internet listing. The FDA's cardiovascular indication announcement for Wegovy injection is a concrete example: it concerns adults with cardiovascular disease and obesity or overweight. It is not a blanket prevention claim for every person using semaglutide.
STEP 1: the widely quoted weight-loss result
In STEP 1, 1,961 adults with obesity, or overweight with a weight-related condition, and without diabetes were randomized to subcutaneous semaglutide or placebo for 68 weeks, alongside lifestyle intervention. Mean weight change was −14.9% with semaglutide and −2.4% with placebo under the treatment-policy estimand. That analysis addresses outcomes regardless of treatment discontinuation or rescue intervention.
The study is direct human evidence for its tested intervention, not simply a mechanistic prediction. Still, it describes a defined population and duration. It does not mean every participant lost the average amount, establish indefinite maintenance after stopping, or prove that an unrelated product contains the studied drug. Its results should remain attached to the trial design rather than becoming an unconditional marketing promise.
SELECT asked a different and clinically important question
The SELECT trial enrolled 17,604 people with established cardiovascular disease and overweight or obesity, without diabetes. Over a mean follow-up of 39.8 months, the composite of cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 6.5% receiving semaglutide and 8.0% receiving placebo. The hazard ratio was 0.80.
A hazard ratio of 0.80 is commonly described as a 20% relative reduction; it is not a 20-percentage-point absolute reduction. The observed event proportions differed by 1.5 percentage points over this trial's follow-up. Permanent treatment discontinuation because of adverse events was more frequent with semaglutide. This is a specific secondary-prevention population, not proof of the same benefit in people without established cardiovascular disease.
Weight change and cardiovascular outcomes are not interchangeable
A drug may have strong evidence on one endpoint without automatically inheriting another drug's evidence on a different endpoint. The SURMOUNT-5 randomized comparison found greater mean weight reduction with tirzepatide than semaglutide in the studied adults and regimens. That does not by itself answer which intervention produces better cardiovascular outcomes or is appropriate for an individual.
Similarly, SELECT does not prove that all of its effect is explained by kilograms lost, nor does it transform every GLP-1-related substance into an equivalent therapy. Readers should identify whether a claim concerns weight, glycemic control, symptoms or a hard clinical event. Each needs evidence matched to that question and population.
Read absolute and relative effects together
Absolute event rates make a relative result interpretable. The same relative reduction would imply different absolute differences in populations with different underlying risks. SELECT therefore should not be advertised as if its event rates were predictions for someone with no established cardiovascular disease. It also should not be dismissed merely because the percentage-point difference is smaller than the relative percentage: the two numbers describe different aspects of the same comparison.
Questions about safety, salts and unapproved products
The FDA's unapproved-drug notice addresses quality and dosing concerns with unapproved GLP-1 products and distinguishes certain semaglutide salts from the active ingredient used in approved drugs. A molecule name, purity claim or research-use label cannot establish pharmaceutical equivalence, sterility or clinical safety.
Does approval mean no risks? No. A complete safety assessment requires the current product label and clinical context, not just a weight-loss percentage. Are oral and injectable results interchangeable? Not without formulation-specific evidence. Can the trial regimen become a self-treatment plan? This guide provides no administration, mixing or escalation instructions. Its purpose is to explain what strong human studies show while preserving the boundaries of their products, outcomes and populations.